According to filings with the U.S. Securities and Exchange Commission, Quantile Health is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management Director, Sidra Ahmed played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Quantile Health
Making Transformative Medicine Accessible to Every Patient. Gene, Cell and ASO therapies are changing the lives of patients and families devastated by rare diseases. These medicines offer the remarkable hope of a life-saving, potentially curative treatment for previously untreatable diseases. And with 2,500+ trials in the pipeline and a growth rate of 25% per year, this industry is poised to revolutionize medicine. However, these high-cost, ultra-rare therapies also pose unique challenges for payers across the world when it comes to coverage and reimbursement. Without a payment solution as innovative as the cures themselves, we anticipate patient access becoming a structural issue within 2-3 years, with the burden ultimately falling upon patients and families. Quantile Health is solving the problem of patient access to gene and cell therapies by creating a payment platform that allows payers to directly enter value-based risk deals with manufactuers.

To learn more about Quantile Health, visit http://quantilehealth.com/

Contact:
Sidra Ahmed, Director
201-374-0601

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.